Visão geral da empresa
A commercial-stage biotechnology firm, Ionis Pharmaceuticals, Inc. specializes in the development and provision of RNA-targeted medicines specifically for the United States market. The company operates within the Healthcare sector, functioning specifically in the Biotechnology industry, which implies a focus on high-risk, high-reward drug discovery and clinical development cycles. Its operational scale is substantial, evidenced by a market capitalization of $12.39B and a workforce comprising 1402 employees. These valuation and revenue figures indicate that Ionis holds a significant position in the biotech landscape, supported by a revenue stream of $943.71M (TTM) that underpins its current market valuation despite ongoing investment in product pipelines such as TRYNGOLZA and DAWNZERA.
Saúde financeira
Ionis Pharmaceuticals reported a revenue of $943.71M (TTM) alongside a net income of $-381,387,008 and an EBITDA of $-369,236,992. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development costs inherent to the biotechnology sector. The company generated free cash flow of $-154,724,496, which indicates a period of capital expenditure exceeding operational cash generation, a common scenario for biotech firms investing heavily in pipeline advancement. Margins reflect this financial reality, with a gross margin of 1.3%, an operating margin of -105.5%, and a profit margin of -40.4%. The negative operating margin suggests that operating expenses currently exceed gross revenue, while the negative profit margin confirms that the company is not yet profitable on a bottom-line basis. On the balance sheet, Ionis holds $2.68B in cash against $2.62B in debt, resulting in a debt-to-equity ratio of 534.84. This leverage ratio indicates a highly leveraged capital structure, although the substantial cash hoard provides a significant buffer against short-term solvency concerns. Liquidity is robust, as demonstrated by a current ratio of 3.83, which signifies that the company possesses more than three times the current assets necessary to cover its current liabilities. Return metrics further highlight the challenges of the current stage, with a return on equity of -70.8% and a return on assets of -7.3%, revealing that management is currently deploying capital to generate losses rather than positive returns for shareholders.
Avaliação de valorização
Valuation metrics for Ionis present a complex picture due to the lack of traditional profitability measures, with a trailing P/E (TTM) listed as N/A and a forward P/E of -120.53. The negative forward P/E implies that the market is pricing in future earnings that are currently projected to be negative, reflecting expectations of continued investment before profitability is achieved. The price-to-book ratio stands at 25.04, indicating that the market values the company at a significant premium over its net asset value, a common valuation characteristic for biotech firms with valuable intellectual property. Alternative valuation multiples such as the price-to-sales ratio of 13.12 and an EV/EBITDA of -33.37 suggest that investors are primarily valuing the company based on its revenue potential and pipeline assets rather than current earnings power. Regarding price volatility, the stock has traded between a 52-week low of $23.95 and a 52-week high of $86.74. Without a specific current price provided in the data, the range itself illustrates the substantial price discovery phase the asset has undergone over the last year. The beta value of 0.40 indicates that the stock exhibits lower volatility relative to the broader market, moving less than half as much as the market index on average.
Growth & Income
Revenue growth year-over-year is recorded at -10.3%, while earnings growth is N/A. The decline in revenue suggests a contraction in sales, whereas the absence of earnings growth data aligns with the company's current unprofitable status and lack of net income. Since the company reports a negative net income, traditional earnings growth comparisons are not applicable in the conventional sense, as the primary focus remains on achieving profitability rather than expanding earnings per share. As a non-dividend payer, Ionis does not distribute a dividend yield or maintains a payout ratio of 0.0%, which means the company reinvests all available capital back into research, development, and operational expansion rather than providing income to shareholders. This approach is typical for biotechnology companies that prioritize long-term product development over short-term income distribution. The overall growth and income profile is defined by revenue contraction in the current period and a complete absence of dividend income, focusing entirely on capital preservation and pipeline progression.